- Home
- HIVE vs SVRA Comparison
HIVE vs SVRA Comparison
Compare HIVE & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- SVRA
- Stock Information
- Founded
- HIVE 1987
- SVRA N/A
- Country
- HIVE Canada
- SVRA United States
- Employees
- HIVE N/A
- SVRA N/A
- Industry
- HIVE
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- HIVE
- SVRA Health Care
- Exchange
- HIVE Nasdaq
- SVRA Nasdaq
- Market Cap
- HIVE 527.8M
- SVRA 540.6M
- IPO Year
- HIVE N/A
- SVRA N/A
- Fundamental
- Price
- HIVE $3.35
- SVRA $3.05
- Analyst Decision
- HIVE Strong Buy
- SVRA Buy
- Analyst Count
- HIVE 6
- SVRA 7
- Target Price
- HIVE $7.42
- SVRA $9.86
- AVG Volume (30 Days)
- HIVE 9.6M
- SVRA 1.1M
- Earning Date
- HIVE 02-11-2025
- SVRA 11-12-2024
- Dividend Yield
- HIVE N/A
- SVRA N/A
- EPS Growth
- HIVE N/A
- SVRA N/A
- EPS
- HIVE N/A
- SVRA N/A
- Revenue
- HIVE $123,022,000.00
- SVRA N/A
- Revenue This Year
- HIVE N/A
- SVRA N/A
- Revenue Next Year
- HIVE N/A
- SVRA N/A
- P/E Ratio
- HIVE N/A
- SVRA N/A
- Revenue Growth
- HIVE 55.97
- SVRA N/A
- 52 Week Low
- HIVE $2.18
- SVRA $2.82
- 52 Week High
- HIVE $5.54
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- HIVE 46.58
- SVRA 41.04
- Support Level
- HIVE $2.76
- SVRA $3.01
- Resistance Level
- HIVE $3.14
- SVRA $3.16
- Average True Range (ATR)
- HIVE 0.25
- SVRA 0.16
- MACD
- HIVE 0.01
- SVRA -0.01
- Stochastic Oscillator
- HIVE 42.45
- SVRA 14.81
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.